Targeting Hirsutism: A New Approach

    Boaz Kurtis, Sarah Brenner
    Studysummary This review discusses the use of eflornithine cream for managing hirsutism in women and reports promising results from clinical experience but presents no new clinical trials. Our plain-language summary of this paper — not a Tressless recommendation.
    The document discussed a new approach to targeting hirsutism, emphasizing the importance of a thorough patient history to evaluate hair growth and distribution. It highlighted that 70%-80% of hirsutism cases are due to androgen-dependent disorders. Treatment options included mechanical hair removal methods, laser hair removal, and electrolysis. The document concluded that eflornithine HCl 13.9% cream (Vaniqa) was an effective FDA-approved topical treatment for reducing and potentially eradicating unwanted facial hair in women, with a favorable side effect profile, and should be considered by physicians for treating hirsutism.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results